INFI - Infinity Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
INFI price evolution
INFI
| (in millions $) | 30 Jun 2023 | 31 Mar 2023 | 31 Jan 2023 | 30 Sep 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $17.9 | $25.89 | $38.31 | $47.18 |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $19.91 | $28.36 | $40.3 | $49.35 |
| Long term investments | $0.16 | $0.16 | ||
| Property, plant & equipment | $1.08 | $1.29 | $1.5 | $1.7 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $1.32 | $1.59 | $1.85 | $2.24 |
| Total investments | $0.16 | $0.16 | ||
| Total assets | $21.23 | $29.95 | $42.15 | $51.59 |
| Current liabilities | ||||
| Accounts payable | $1.5 | $1.94 | $4.41 | $1.95 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $12.06 | $11.29 | $13.63 | $14.2 |
| Long term debt | $0.16 | $0.32 | $0.48 | |
| Total noncurrent liabilities | $46.57 | $46.98 | $47.57 | $48.27 |
| Total debt | $0.16 | $0.32 | $0.48 | |
| Total liabilities | $58.64 | $58.27 | $61.2 | $62.47 |
| Shareholders' equity | ||||
| Retained earnings | -$876.95 | -$867 | -$855.95 | -$846.72 |
| Other shareholder equity | ||||
| Total shareholder equity | -$37.41 | -$28.32 | -$19.05 | -$10.87 |
| (in millions $) | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $38.31 | $80.73 | $28.59 | $22.57 |
| Short term investments | $5.51 | $20.18 | ||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $40.3 | $82.27 | $36.02 | $44.58 |
| Long term investments | $0.16 | $0.16 | $0.17 | |
| Property, plant & equipment | $1.5 | $2.31 | $3.13 | $3.9 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $1.85 | $2.52 | $3.3 | $4.43 |
| Total investments | $0.16 | $0.16 | $5.68 | $20.18 |
| Total assets | $42.15 | $84.78 | $39.32 | $49.01 |
| Current liabilities | ||||
| Accounts payable | $4.41 | $2.32 | $2.98 | $1.62 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $13.63 | $13.3 | $11.05 | $9.7 |
| Long term debt | $0.32 | $0.92 | $1.44 | $1.93 |
| Total noncurrent liabilities | $47.57 | $49.91 | $51.26 | $31.59 |
| Total debt | $0.32 | $0.92 | $1.44 | $1.93 |
| Total liabilities | $61.2 | $63.21 | $62.31 | $41.29 |
| Shareholders' equity | ||||
| Retained earnings | -$855.95 | -$811.58 | -$766.32 | -$725.83 |
| Other shareholder equity | -$0 | $0.01 | ||
| Total shareholder equity | -$19.05 | $21.57 | -$22.99 | $7.73 |
| (in millions $) | 30 Jun 2023 | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.58 | $0.73 | $0.54 | $0.71 |
| Cost of revenue | ||||
| Gross Profit | $0.58 | $0.73 | $0.54 | $0.71 |
| Operating activities | ||||
| Research & development | $6.6 | $5.85 | $6.96 | $7.66 |
| Selling, general & administrative | $3.75 | $5.94 | $2.79 | $3.5 |
| Total operating expenses | $10.7 | $12.24 | $10.08 | $11.59 |
| Operating income | -$10.12 | -$11.51 | -$9.54 | -$10.88 |
| Income from continuing operations | ||||
| EBIT | -$9.91 | -$11 | -$9.19 | -$10.67 |
| Income tax expense | ||||
| Interest expense | $0.04 | $0.04 | $0.04 | $0.04 |
| Net income | ||||
| Net income | -$9.96 | -$11.04 | -$9.23 | -$10.72 |
| Income (for common shares) | -$9.96 | -$11.04 | -$9.23 | -$10.72 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2.59 | $1.86 | $1.72 | $3.05 |
| Cost of revenue | ||||
| Gross Profit | $2.59 | $1.86 | $1.72 | $3.05 |
| Operating activities | ||||
| Research & development | $32.41 | $31.65 | $26.76 | $27.12 |
| Selling, general & administrative | $13.46 | $14.17 | $12.42 | $14.29 |
| Total operating expenses | $47.44 | $46.94 | $40.22 | $48.71 |
| Operating income | -$44.84 | -$45.08 | -$38.5 | -$45.66 |
| Income from continuing operations | ||||
| EBIT | -$44.19 | -$45.08 | -$38.05 | -$44.55 |
| Income tax expense | -$0.05 | |||
| Interest expense | $0.18 | $0.18 | $2.44 | $2.56 |
| Net income | ||||
| Net income | -$44.37 | -$45.26 | -$40.49 | -$47.06 |
| Income (for common shares) | -$44.37 | -$45.26 | -$40.49 | -$47.06 |
| (in millions $) | 30 Jun 2023 | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 |
|---|---|---|---|---|
| Net income | -$9.96 | -$11.04 | -$9.23 | -$10.72 |
| Operating activities | ||||
| Depreciation | $0.11 | $0.1 | $0.11 | $0.11 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.86 | $1.77 | $1.02 | $0.92 |
| Total cash flows from operations | -$8.01 | -$12.58 | -$8.9 | -$9.4 |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | $10.73 | |||
| Total cash flows from investing | $10.73 | |||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.03 | $0.01 | ||
| Net borrowings | ||||
| Total cash flows from financing | $0.03 | $0.01 | ||
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$7.99 | -$12.58 | -$8.87 | $1.34 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Net income | -$44.37 | -$45.26 | -$40.49 | -$47.06 |
| Operating activities | ||||
| Depreciation | $0.46 | $0.48 | $0.48 | $0.22 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $3.62 | $2.69 | $1.46 | $2.13 |
| Total cash flows from operations | -$42.43 | -$40.62 | -$35.74 | -$41.53 |
| Investing activities | ||||
| Capital expenditures | -$0.02 | -$0.01 | -$0.04 | -$2.33 |
| Investments | -$0.04 | $5.5 | $14.67 | -$9.91 |
| Total cash flows from investing | -$0.06 | $5.49 | $14.63 | -$12.24 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.07 | $87.11 | $7.87 | $0.11 |
| Net borrowings | ||||
| Total cash flows from financing | $0.07 | $87.11 | $27.44 | $27.73 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$42.41 | $51.98 | $6.33 | -$26.04 |
News
Fundamentals
| Market cap | $331.28K |
|---|---|
| Enterprise value | -$17.57M |
| Shares outstanding | 90.76M |
| Revenue | $2.57M |
|---|---|
| EBITDA | -$40.34M |
| EBIT | -$40.77M |
| Net Income | -$40.95M |
| Revenue Q/Q | -15.01% |
| Revenue Y/Y | 15.88% |
| P/E ratio | -0.01 |
|---|---|
| EV/Sales | -6.84 |
| EV/EBITDA | 0.44 |
| EV/EBIT | 0.43 |
| P/S ratio | 0.13 |
| P/B ratio | -0.01 |
| Book/Share | -0.41 |
| Cash/Share | 0.20 |
| EPS | -$0.45 |
|---|---|
| ROA | -113.02% |
| ROE | 171.24% |
| Debt/Equity | -3.21 |
|---|---|
| Net debt/EBITDA | -1.01 |
| Current ratio | 1.65 |
| Quick ratio | 1.65 |